Inhibrx Biosciences, Inc.: Schonfeld Strategic Advisors LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Schonfeld Strategic Advisors LLC amended its Schedule 13G stake filing for Inhibrx Biosciences, Inc., according to SEC accession 0001193805-26-001466. The amendment updates the investment adviser's reported position in the clinical-stage biopharmaceutical company. Schedule 13G filings are required of investors holding passive stakes above 5% of a class of securities, so the revision signals a change in Schonfeld's beneficial ownership. The filing did not disclose the exact size of the stake or the direction of the change in the headline. Investors will watch for further 13G or 13D filings to clarify whether Schonfeld is building or trimming its position in Inhibrx.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Schonfeld Strategic Advisors LLC, Inhibrx Biosciences, Inc.